Company Market News

Takeda Pharmaceutical Co. Ltd. (NYSE: TAK)
9:00 PM UTC, 12/12/25
Last: $14.33 Change: -0.06 %Change: -0.42% Volume: 2,123,444
Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug

Back

Last updated: 02/24/2025 4:26:54 AM

04:26 AM EST, 02/24/2025 (MT Newswires) -- Takeda Pharmaceutical Co (TAK) said Monday that the European Medicines Agency has approved an additional subcutaneous administration option for hereditary angioedema drug TAKHZYRO, or lanadelumab.

The drug now comes in a 2 mL pre-filled pen for adolescent and adult patients, the company said.

Hereditary angioedema is a rare genetic disease that causes severe swelling in the body.

http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.




Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.